Drug intelligence / Profile preview

eledoisin

Development stage
Unknown
Modality
Peptides
Administration
Experimental (laboratory/research Use Only)
01

Overview

Eledoisin is a naturally occurring undecapeptide (11 amino acids) neuropeptide of the tachykinin family, originally isolated from the posterior salivary glands of Mediterranean octopuses (*Eledone moschata* and *E. aldovandi*)[4][8]. It acts as a potent agonist at neurokinin receptors, especially NK1 and NK2, mediating smooth muscle contraction and sensory neurotransmission[1][4]. Eledoisin exhibits pharmacological activities such as vasodilation, increased capillary permeability, stimulation of extravascular smooth muscle contraction, and modulation of ion transport in certain tissues[4][6][8]. Its sequence is pGlu-Pro‑Ser‑Lys‑Asp‑Ala‑Phe‑Ile‑Gly‑Leu‑Met-NH2. While it has been widely used in research to study tachykinins and their receptors due to its availability before mammalian tachykinins were characterized, it is not approved for clinical use in humans[5][6].

Other names
eledoisin [inn]eledoisinumeledoisinaeledoisineeledoisine [inn-french]eledoisina [inn-spanish]
02

Targets

TACR3 (Neurokinin 3 Receptor)TACR1 (Neurokinin‑1 Receptor)TACR2 (Neurokinin-2 Receptor)

Beyond the preview

Go deeper on eledoisin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on eledoisin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call